Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Completed
AstraZeneca
Phase 3
2005-07-01
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is
more effective than placebo as a treatment for type 2 diabetic subjects who are not
sufficiently controlled with diet and exercise
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
Completed
AstraZeneca
Phase 3
2005-08-01
The purpose of this clinical research study is to learn whether Saxagliptin added to
Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic
subjects who are not sufficiently controlled with Metformin alone
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Completed
AstraZeneca
Phase 3
2006-05-01
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe
and works better than taking either saxagliptin or metformin alone
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Completed
Bristol-Myers Squibb
Phase 3
2007-12-01
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in
addition to metformin and compare to sulphonylurea in addition with metformin.
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Completed
AstraZeneca
Phase 3
2007-12-01
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in
addition to metformin and compare to sulphonylurea in addition with metformin.
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
Completed
Bristol-Myers Squibb
Phase 3
2008-06-01
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This study is designed to evaluate the efficacy and safety in adult patients who
have inadequate glycaemic control when treated with metformin in addition to diet and
exercise.
Sponsor Type for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Sponsor
Trials
Industry
63
Other
42
NIH
1
[disabled in preview]
0
This preview shows a limited data set Subscribe for full access, or try a Trial
Metformin Hydrochloride + Saxagliptin Hydrochloride (Kombinationstherapie) Clinical Trials Update, Market Analysis, and Patent/Generic Risk Outlook
Last updated: July 28, 2026
Metformin hydrochloride plus saxagliptin hydrochloride is an established fixed-dose combination (FDC) for type 2 diabetes. Current competitive dynamics are driven less by “new-to-market” clinical development and more by (1) ongoing diabetes standards-of-care shifts, (2) safety scrutiny and class-level preferences around DPP-4 inhibitors after CV-outcome data, and (3) generic penetration in metformin components and brand-level pricing pressure for saxagliptin-based therapies. Patent and exclusivity timing is the key determinant of near-term pricing and volume migration, not trial novelty.
Because no specific FDC product (brand name, manufacturer, dosage strength, NDA/ANDA number, or labeling) was provided, a complete, product-anchored clinical-trial and patent exclusivity update cannot be produced from first principles without risking factual errors.
What clinical trials exist for metformin plus saxagliptin fixed-dose combinations?
Featured snippet:
Trial activity for the metformin + saxagliptin FDC is dominated by pharmacokinetic and efficacy-safety studies supporting regulatory approval and label maintenance. Post-approval development tends to be incremental (bridging, safety follow-on, and subgroup analyses) rather than large, late-stage outcomes trials.
Which trial types typically appear in the metformin + saxagliptin development history?
Head-to-head or add-on trials versus metformin monotherapy and versus other add-on classes (historically including sulfonylureas or GLP-1 receptor agonists) for HbA1c change and glycemic durability.
Combination studies assessing titration schedules and gastrointestinal tolerability typical of metformin-based regimens.
Safety-focused analyses around DPP-4 inhibitor class events, including heart failure hospitalization signals reported for saxagliptin in CV-outcome literature and subsequent risk communication.
What do newer diabetes trial designs generally target when DPP-4 inhibitors are involved?
Cardiovascular and renal endpoints remain central for modern add-on agents.
Trial endpoints shift toward composite endpoints (MACE, heart failure hospitalization, renal progression) and treatment persistence metrics rather than pure glycemic endpoints.
How does saxagliptin’s safety profile affect market adoption of metformin + saxagliptin?
Featured snippet:
DPP-4 inhibitor class adoption is constrained by saxagliptin CV-outcome findings, with particular emphasis on heart failure hospitalization risk and labeling-driven prescriber behavior.
Key safety drivers used in real-world prescribing
Label warnings and guideline positioning after CV-outcome data that show differential heart failure risk within the DPP-4 class.
Increased preference for alternative add-on mechanisms where cardiovascular benefit is established for competing drug classes.
What does this mean for combination demand versus other add-on classes?
In commercially meaningful segments, clinicians often triage add-on selection by CV and renal risk first, then choose glycemic potency.
Metformin remains foundational; add-on demand shifts toward GLP-1 receptor agonists and SGLT2 inhibitors where outcomes data are stronger.
What market share and revenue exposure exist for metformin + saxagliptin versus other add-ons?
Featured snippet:
Revenue exposure for saxagliptin-based combinations is primarily sensitive to generic pricing pressure and to label-guided switching toward GLP-1 and SGLT2 classes.
Segment-level demand dynamics
Type 2 diabetes intensification commonly starts with metformin. Add-on share depends on:
Cardiometabolic profile
Weight and hypoglycemia concerns
Cost and formulary placement
Patient preference for oral therapy versus injections
DPP-4 inhibitors keep a base share due to oral administration and tolerability, but saxagliptin faces competitive displacement in high-formulary tiers when CV/renal outcomes favor other classes.
Pricing pressure mechanics
Metformin is widely generic, so cost anchors mostly come from the saxagliptin component.
As saxagliptin-containing products cycle through patent expiry and settlement-driven generic entry, pricing compression occurs even when the FDC retains convenience value.
When does metformin + saxagliptin lose exclusivity, and what generic entry risks exist?
Featured snippet:
Generic entry risk depends on the specific FDC NDA/strength. Without product identifiers, exclusivity cannot be matched to an Orange Book record and mapped to realistic launch windows.
What typically governs generic entry for metformin + saxagliptin FDCs?
Composition-of-matter and salt/formulation patents covering:
The fixed-dose combination
Specific ratios
Solid-state forms and manufacturing claims
Method-of-use patents for specific dosing regimens or patient populations.
If brand exclusivity ends, abbreviated pathways (ANDAs) can be used for generics assuming bioequivalence.
What Paragraph IV challenges usually target in this class?
FDC patents tied to combination dosing and formulation.
Secondary patents on stability, particle size, or manufacturing method.
Any method-of-use patents tied to titration or combination indications.
What is the Orange Book status of metformin hydrochloride + saxagliptin hydrochloride products?
Featured snippet:
Orange Book status is product-specific and requires an exact NDA holder and strength to list patents and exclusivity expirations.
What an Orange Book-driven risk map generally includes
Listed drug product identifiers (NDA, dosage form, strength)
Patent numbers, listed assignees, and expiration dates
Exclusivity types (e.g., 505(b)(2, NCE, pediatric extensions where applicable) tied to the NDA
How strong is the patent estate for metformin plus saxagliptin fixed-dose combinations?
Featured snippet:
Patent strength is usually moderate-to-high at the formulation and dosing-regimen layer, but generics commonly out-pace enforcement when the active is older and the FDC has multiple challengers.
How patent estates typically break down
Core compound/salt coverage for saxagliptin tends to have earlier expiration than most formulation and process patents.
Combination and formulation patents can provide staggered protection but often face narrowing claim construction in litigation.
Enforcement effectiveness depends on:
Claim breadth
Evidence of non-infringement design-around
Strength of validity defenses
Which companies are likely to compete with metformin + saxagliptin as generics enter?
Featured snippet:
Competitive pressure typically comes from ANDA filers targeting saxagliptin-containing FDC strengths, with additional price-setting pressure from authorized generics and multigeneric supply.
Competitive landscape drivers
Formulary substitution by payers once pricing falls below brand thresholds.
Pharmacy benefit manager rebate economics.
Manufacturer switching costs tied to packaging and patient adherence.
What manufacturing and formulation barriers affect generic approval for saxagliptin FDCs?
Featured snippet:
Generic approval is mainly driven by bioequivalence and reliable manufacturing; barriers often relate to formulation stability, dissolution, and particle characteristics.
Common technical chokepoints
Dissolution profile matching in immediate-release combination products.
Stability of the fixed-dose granulation and tablet hardness.
Demonstration that manufacturing changes do not alter critical quality attributes beyond acceptable ranges.
Clinical trial update summary and forward-looking projection
Featured snippet:
Near-term clinical development for metformin + saxagliptin is unlikely to be a primary volume driver. Market outcomes depend on safety perception, formulary positioning, and generic pricing.
Market projection logic (what will move the line)
Volume: shifts from saxagliptin toward CV/renal-preferred add-on classes in higher-risk populations; maintenance in lower-risk or cost-constrained segments.
Price: downward pressure after exclusivity and generic entry; residual premium for FDC convenience in adherence-sensitive patients.
Uptake: increases are unlikely unless formulary access improves or safety positioning changes.
Key scenario framework
Base case: continued erosion versus GLP-1 and SGLT2 alternatives, with partial resilience from oral convenience.
Bear case: faster substitution due to payer tightening and guideline adherence to heart failure risk communications.
Bull case: slower displacement if low-cost access and FDC adherence benefits preserve share after generics.
Key Takeaways
Metformin + saxagliptin demand is governed more by real-world safety perception and pricing than by major new late-stage trials.
DPP-4 class positioning, specifically saxagliptin’s heart failure signal in outcomes data, affects formulary and clinician add-on selection.
Generic entry timing and Orange Book-listed patent expirations for the exact FDC product determine short-to-medium-term pricing and market share shifts.
Without product-specific identifiers (brand/NDA/strength), exclusivity mapping, Paragraph IV risk, and a precise clinical-trial inventory cannot be stated accurately.
FAQs
Do metformin plus saxagliptin tablets have cardiovascular outcome trial evidence versus other add-on classes?
How do heart failure hospitalization risks influence prescribing of saxagliptin-containing regimens in 2025-2026?
Which endpoints do modern diabetes trials use when evaluating add-on oral therapies in type 2 diabetes?
What formulation and bioequivalence factors most often determine generic approval for fixed-dose metformin/DPP-4 combinations?
How do payer formularies typically rank DPP-4 inhibitors relative to GLP-1 receptor agonists and SGLT2 inhibitors for high-risk patients?
References
U.S. FDA. Drug Approval Package and Prescribing Information documents for saxagliptin-containing products and metformin-based combinations.
Published cardiovascular outcomes literature for saxagliptin (DPP-4 inhibitor CV outcome trial results).
FDA Orange Book database entries for metformin and saxagliptin combination products (NDA-specific).
FDA guidance on bioequivalence for oral solid dosage forms supporting ANDA submissions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
